by University of Southern California Credit: Shutterstock Biosimilars provide the same therapeutic benefits at much less cost than biologic medications, yet slow marketplace acceptance has prevented their advantages from being fully realized. A new study led by USC Schaeffer Center Fellow Jakub Hlávka finds insurers either excluded or imposed restrictions on biosimilars in 19.4% of the...
